Invitation to Capital Markets Day on November 11 Vitrolife

Vitrolife AB (publ) hereby invites analysts, investors, shareholders and journalists to a Capital Markets Day on November 11. We will talk about Vitrolife’s business, which assists in making many people’s desire to have children a reality. During 2012 Vitrolife contributed to the birth of an estimated 70,000 children. We will give an update on the operative and financial development of the Vitrolife Group and look deeper into the future of the IVF field. There will be an opportunity to visit one of our production facilities and to see how some of our most important products are used. Time November 11, 4 pm – 7 pm. Venue Vitrolife’s headquarters, Gustaf Werners gata 2, 421 32 Västra Frölunda/Gothenburg. Registration Please inform Anita Ahlqvist that you will attend by email, aahlqvist@vitrolife.com, or by telephone on +46 (0)31–721 80 83, no later than October 30. A light meal will be served, so please inform us of any allergies you may have. There is a limited number of places. For the full program, please visit www.vitrolife.com. The presentation will be held in Swedish. Gothenburg, October 8, 2013 VITROLIFE AB (publ) Queries should be addressed to: Thomas Axelsson, CEO, tel 46 31 721 80 01 Mikael Engblom, CFO, tel 46 31 721 80 14 Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on October 8, 2013 at 08:30 a.m. This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails. ________________________________________________________________________________ _ ________________________________ Vitrolife (http://www.vitrolife.com/en/Corporate/) is an international medical device Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 230 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is listed on NASDAQ OMX Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE 1 3469), Small Cap. ________________________________________________________________________________ _ ________________________________ Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/